复星医药(02196)控股子公司就诊疗一体化核药项目SRT-007 于中国境内启动Ⅰ期临床试验

Core Viewpoint - Fosun Pharma (02196) has initiated Phase I clinical trials for its integrated diagnostic and therapeutic nuclear medicine project SRT-007 in mainland China, targeting PSMA-positive metastatic castration-resistant prostate cancer [1] Group 1 - The project SRT-007 is developed by Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., a subsidiary of Fosun Pharma [1] - The indication for SRT-007 is focused on the diagnosis and treatment of prostate cancer that is resistant to castration and has metastasized [1]